1702967-37-0

Basic information

• Product Name: PMSA-617
• CAS NO: 1702967-37-0
• Molecular Weight: 1042.15
• Mol File: 1702967-37-0.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 1371.9±65.0 °C(Predicted)
• Density: 1.322±0.06 g/cm3(Predicted)
• CAS DataBase Reference: PMSA-617(CAS DataBase Reference)
• NIST Chemistry Reference: PMSA-617(1702967-37-0)
• EPA Substance Registry System: PMSA-617(1702967-37-0)

Safety Data

• Hazardous Substances Data: 1702967-37-0(Hazardous Substances Data)

Usage

Description

PMSA-617 is a prostate-specific membrane antigen-targeted theranostic agent that has shown promise in prostate cancer research.

Uses

Used in Prostate Cancer Research:
PMSA-617 is used as a theranostic agent for targeting prostate-specific membrane antigen in prostate cancer treatment. It has the potential to improve the efficacy and selectivity of treatment for this type of cancer.

Upstream product

• 167690-53-1 (1R,4R)-4-[({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)methyl]cyclohexane-1-carboxylic acid 
• 137076-54-1 1,4,7-tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane-10-acetic acid 
• 170908-81-3 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid mono(N-hydroxysuccinimidyl ester) 
• 138774-94-4 N-(9-fluorenylmethoxycarbonyl)-3-(β-naphthyl)-L-alanine 

Relevant articles and documents

Linker Modification Strategies to Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors

Since prostate-specific membrane antigen (PSMA) is up-regulated in nearly all stages of prostate cancer (PCa), PSMA can be considered as a viable diagnostic biomarker and treatment target in PCa. This project is focused on the development and evaluation of a series of compounds directed against PSMA. The modifications to the linker are designed to improve the binding potential and pharmacokinetics for theranostic application. In addition, the results help to further elucidate the structure-activity relationships (SAR) of the resulting PSMA inhibitors. Both in vitro and in vivo experiments of 18 synthesized PSMA inhibitor variants showed that systematic chemical modification of the linker has a significant impact on the tumor-targeting and pharmacokinetic properties. This approach can lead to an improved management of patients suffering from recurrent prostate cancer by the use of one radiolabeling precursor, which can be radiolabeled either with 68Ga for diagnosis or with 177Lu or 225Ac for therapy.

TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER

A compound of general formula (I): wherein: n is 1, 2 or 3; R1, R2, R3 and R4, independently represent OH or Q; and 20 Q represents a tissue-targeting moeity selected from the group consisting of or a stereoisomer, a hydrate, a solvate, or a salt thereof, or a mixture of same, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said 25 compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of soft tissue diseases, as a sole agent or in combination with other active ingredients.

NOVEL RADIOMETAL-BINDING COMPOUNDS FOR DIAGNOSIS OR TREATMENT OF PROSTATE SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CANCER

This application relates to compounds of Formula (I-a) or Formula (I-b), or is salts or solvates thereof. R1 is -(CH2)5CH3 or comprises 2-4 fused benzene rings. R2 is I, Br, F, Cl, H, OH, OCH3/s